Evidence map›Paper›PMID 42822410›Full record

ArticleJACC. Advances2026

Absence of Fibrosis Influences Prognosis of Cardiac Resynchronization in Nonischemic Cardiomyopathy: Systematic Review and Meta-Analysis.

Jesús Sánchez-Vega, Ignasi Anguera, Francisco Leyva, Otto A Smiseth, Jens-Uwe Voigt, Juan Fernandez-Armenta, Markus Linhart, Antonio Berruezo, Shunmuga Sundaram Ponnusamy, Arnaud Bisson and 11 more

Abstract read
In one paragraph

Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jesús Sánchez-VegaDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: https://twitter.com/jesussv89.
Ignasi AngueraDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Francisco LeyvaUniversity Hospitals Birmingham Queen Elizabeth, Birmingham, United Kingdom.
Otto A SmisethDivision of Cardiovascular and Pulmonary Diseases, Institute for Surgical Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
Jens-Uwe VoigtDepartment of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
Juan Fernandez-ArmentaDepartment of Cardiology, Puerta del Mar University Hospital, Cádiz, Spain.
Markus LinhartCardiology Department, University Hospital Doctor Josep Trueta, Girona, Spain.
Antonio BerruezoQuironsalud Group, Teknon Medical Center, Arrhythmia Department, Heart Institute, Barcelona, Spain.
Shunmuga Sundaram PonnusamyDepartment of Cardiology, Velammal Medical College Hospital and Research Institute, Madurai, India.
Arnaud BissonService de Cardiologie, Centre Hospitalier Régional Universitaire et Université de Tours, Tours, France.
Giulio ConteCardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Francesco MaffessantiMaria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Alejandro Ruiz-MajoralDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Marta Gonzalez-LoperaDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Eduard Claver-GarridoDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Laia Lorenzo-EstellerDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Fernando de FrutosDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Gemma Mateus-PortaDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Jesus Rodriguez-SilvaDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Josep Comin-ColetDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Innovation, Research and Universities Department, Gerència Territorial Metropolitana Sud, Institut Català de la Salut, Spain; Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, CIBER-CV, Madrid, Spain.
Andrea Di MarcoDepartment of Cardiology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, CIBER-CV, Madrid, Spain. Electronic address: adimarco@bellvitgehospital.cat.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with nonischemic cardiomyopathy (NICM) undergoing cardiac resynchronization therapy (CRT), there are no clear recommendations on selecting CRT with defibrillator (CRT-D) vs pacemaker (CRT-P). Patients with high probability of response to CRT and low arrhythmic risk may be ideal candidates to CRT-P.

objectivesThe objectives of the study was to evaluate if the absence of late gadolinium enhancement (LGE) is associated with CRT response and ventricular arrhythmia (VA) in NICM treated with CRT.

methodsA systematic review and meta-analysis was conducted. Search of PubMed, Web of Science, and Scopus identified observational studies of NICM patients who underwent cardiac magnetic resonance before CRT implantation. Studies assessing echocardiographic response to CRT or VA stratified by LGE status were included. The VA endpoint comprised sustained ventricular tachycardia, appropriate implantable cardioverter-defibrillator therapy, resuscitated cardiac arrest, and sudden death.

resultsTen studies were included: 9 (n = 831) for CRT response and 6 (745 patients) for arrhythmic risk. CRT response was significantly higher in patients without LGE than in patients with LGE (78.7% vs 50.7%; P < 0.001). The cumulative incidence of VA was extremely low in LGE cases, significantly lower than that of LGE+ ones (0.8% vs 21.1%, P < 0.001). The absence of LGE was strongly associated with higher CRT response (OR: 3.52; 95% CI: 2.54-4.88; P < 0.001) and much lower arrhythmic risk (OR: 0.06; 95% CI: 0.02-0.15; P < 0.001).

conclusionsIn NICM patients undergoing CRT, the absence of LGE is strongly associated with greater echocardiographic response and very low arrhythmic risk. In this subgroup the incremental benefit of CRT with defibrillator over CRT-P may be limited.

Indexed as

cardiac magnetic resonanceimplantable cardioverter-defibrillatormyocardial fibrosisreverse remodelingsudden cardiac deathventricular arrhythmia

Identifiers

PMID42822410
PMCPMC13653926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.